%PDF-1.4
%
73 0 obj
<>
endobj
70 0 obj
<>
endobj
116 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-09T11:28:57Z
2024-03-28T02:03:49-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T02:03:49-07:00
application/pdf
Heather
2001-587.may02
uuid:c19fbeb5-1dd1-11b2-0a00-5b0927bd3700
uuid:c19fbeb8-1dd1-11b2-0a00-5b0000000000
endstream
endobj
59 0 obj
<>
endobj
60 0 obj
<>
endobj
74 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
25 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
28 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
36 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
44 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
47 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
150 0 obj
[154 0 R]
endobj
151 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 73.2 714.5293 Tm
(composition in fibromyalgia and work-related myalgia. Scand )Tj
0 -1.25 TD
(J Rheumatol 1992;21:28-34.)Tj
-1.65 -1.25 Td
[(4.)-750 (Mengshoel )54.9 (A, )17.8 (V)129.2 (ollestad N, Forre O. Pain and fatigue induced by)]TJ
1.65 -1.25 Td
(exercise in fibromyalgia patients and sedentary healthy subjects.)Tj
T*
(Clin Exp Rheumatol 1995;13:477-82.)Tj
-1.65 -1.25 Td
[(5.)-750 (Jacobsen S, Danneskiold-Samsoe B. Isometric and isokinetic muscle)]TJ
1.65 -1.25 Td
(strength in patients with fibrositis syndrome. Scand J Rheumatol)Tj
0 Tw T*
(1987;16:61-5.)Tj
-0.00011 Tc 0.02499 Tw -1.65 -1.25 Td
[(6.)-750.1 (Mengshoel )54.8 (A, Forre O, Komnaes H. Muscle strength and aerobic)]TJ
0 Tc 1.65 -1.25 Td
(capacity in primary fibromyalgia. Clin Exp Rheumatol 1990;)Tj
0 Tw T*
(8:475-9.)Tj
-0.00011 Tc 0.02499 Tw -1.65 -1.25 Td
[(7.)-750.1 (Lindh M, Johansson G, Hedber)17.7 (g M, Henning G-B, Grimby G.)]TJ
0 Tc 1.65 -1.25 Td
(Muscle fibre characteristics, capillaries and enzymes in patients)Tj
T*
(with fibromyalgia and controls. Scand J Rheumatol 1995;24:34-7.)Tj
-0.00011 Tc -1.65 -1.25 Td
[(8.)-750.1 (Norregaard J, Bulow P)110.7 (,)-0.1 ( L)54.8 (ykkegaard J, Mehlsen J, Danneskiold-)]TJ
0 Tc 1.65 -1.25 Td
[(Samsoe B. Muscle strength, working capacity and ef)17.8 (fort in patients)]TJ
T*
(with fibromyalgia. Scand J Rehabil Med 1997;29:97-102.)Tj
-0.00011 Tc -1.65 -1.25 Td
[(9.)-750.1 (Miller )17.7 (T)73.9 (,)-0.1 ( )54.8 (Allen G, Gandevia S. Muscle force, perceived ef)17.7 (fort, and)]TJ
0 Tc 1.65 -1.25 Td
(voluntary activation of the elbow flexors assessed with sensitive)Tj
T*
(twitch interpolation in fibromyalgia. J Rheumatol 1996;23:1621-7.)Tj
-0.00011 Tc -2.15 -1.25 Td
[(10.)-750.1 (Hakkinen )54.8 (A, Hakkinen K, Hannonen P)110.7 (,)-0.1 ( )54.8 (Alen M. Force production)]TJ
0 Tc 2.15 -1.25 Td
(capacity and acute neuromuscular responses to fatiguing loading in)Tj
T*
[(fibromyalgia women are not dif)17.8 (ferent from those of healthy women.)]TJ
T*
(J Rheumatol 2000;27:1277-82.)Tj
-2.1131 -1.25 Td
[(1)36.9 (1.)-750 (Bennett R, Clark S, Campbell S, Burckhardt C. Somatomedin )]TJ
2.1131 -1.25 Td
(C levels in patients with fibromyalgia syndrome: a possible link)Tj
T*
[(between sleep and muscle pain. )54.9 (Arthritis Rheum 1992;35:1)36.9 (1)36.9 (13-6.)]TJ
-0.00011 Tc -2.15 -1.25 Td
[(12.)-750.1 (Griep E, Boersma J, Kloet E. Pituitary release of growth hormone)]TJ
0 Tc 2.15 -1.25 Td
(and prolactin in the primary fibromyalgia syndrome. J Rheumatol)Tj
0 Tw T*
(1994;21:2125-30.)Tj
0.0249 Tw -2.15 -1.25 Td
[(13.)-750 (Bagge E, Bengtsson B-E, Carlsson L, Carlsson J. Low hormone)]TJ
2.15 -1.25 Td
[(secretion in patients with fibromyalgia \227 )54.8 (A)-219.8 (preliminary report on)]TJ
T*
(10 patients and 10 controls. J Rheumatol 1998;25:145-8.)Tj
-2.15 -1.25 Td
[(14.)-750 (Bennett RM, Clark SC, )17.7 (W)79.8 (alczyk JA. )54.8 (A)-219.8 (randomized, double blind,)]TJ
2.15 -1.25 Td
(placebo-controlled study of growth hormone in the treatment of)Tj
T*
[(fibromyalgia. )54.9 (Am J Med 1998;104:227-31.)]TJ
-2.15 -1.25 Td
[(15.)-750 (Achermann JC, Silverman BL. Dehydroepiandrosterone )]TJ
2.15 -1.25 Td
[(replacement for patients with adrenal insuf)17.8 (ficiency)64.9 (. Lancet)]TJ
0 Tw T*
(2001;357:1381-2.)Tj
0.0249 Tw -2.15 -1.25 Td
[(16.)-750 (Sim J, )54.8 (Adams N. Physical and other non-pharmacological )]TJ
2.15 -1.25 Td
(interventions for fibromyalgia. Clin Rheumatol 1999;13:507-23.)Tj
-0.00011 Tc -2.15 -1.25 Td
[(17.)-750.1 (Craig B, Brown R, Everhart J. Ef)17.7 (fects of progressive resistance)]TJ
0 Tc 2.15 -1.25 Td
(training on growth hormone and testosterone levels in young and)Tj
T*
[(elderly subjects. Mech )54.9 (Aging Devel 1989;49:159-69.)]TJ
-2.15 -1.25 Td
[(18.)-750 (Hakkinen K, Pakarinen )54.9 (A. )54.9 (Acute hormonal responses to heavy )]TJ
2.15 -1.25 Td
[(resistance loading in men and women at dif)17.8 (ferent ages. Int J Sports)]TJ
T*
(Med 1995;16:507-13.)Tj
-2.15 -1.25 Td
[(19.)-750 (Kraemer )17.8 (WJ, Hakkinen K, Newton R, et al. )54.9 (Acute hormonal)]TJ
2.15 -1.25 Td
(responses to heavy resistance exercise in younger and older men.)Tj
T*
[(Eur J )54.8 (Appl Physiol 1998;77:206-1)36.9 (1.)]TJ
-0.00011 Tc 30.85 61.25 Td
[(20.)-750.1 (Hakkinen K, Pakarinen )54.8 (A, Kraemer )17.7 (WJ, Newton RU, )54.8 (Alen M. Basal)]TJ
0 Tc 2.15 -1.25 Td
(concentrations and acute responses of serum hormones and strength)Tj
T*
(development during heavy resistance training in middle-aged and)Tj
T*
(elderly men and women. J Ger Biol Sci 2000;55:95-105.)Tj
-0.00011 Tc -2.15 -1.25 Td
[(21.)-750.1 (Dessein PH, Shipton EA, Jof)17.7 (fe BI, Hadebe DP)110.7 (, Stanwix )54.8 (AE, van der)]TJ
0 Tc 2.15 -1.25 Td
(Merwe BA. Hyposecretion of adrenal androgens and the relation of)Tj
-0.00011 Tc T*
[(serum adrenal steroids, serotonin and insulin like growth factor)19.7 (-I to)]TJ
0 Tc T*
(clinical features with fibromyalgia. Pain 1999;83:313-9.)Tj
-2.15 -1.25 Td
[(22.)-750 (W)79.8 (elle S. Growth hormone and insulin like growth factor)19.8 (-I as)]TJ
2.15 -1.25 Td
(anabolic agents. Curr Opin Clin Nutr Metab Care 1998;1:257-62.)Tj
-2.15 -1.25 Td
[(23.)-750 (W)79.8 (olfe F)79.8 (, Smythe H, )36.8 (Y)111.1 (unus M, et al. )17.7 (The )54.8 (American College of)]TJ
2.15 -1.25 Td
(Rheumatology 1990 criteria for the classification of fibromyalgia.)Tj
T*
[(Report of the Multicenter Criteria Committee. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1990;33:160-72.)Tj
-0.00011 Tc 0.02499 Tw -2.15 -1.25 Td
[(24.)-750.1 (Hakkinen )54.8 (A, Hakkinen K, Hannonen P)110.7 (,)-0.1 ( )54.8 (Alen M. Strength )]TJ
0 Tc 2.15 -1.25 Td
(training-induced adaptations in neuromuscular function of)Tj
T*
(premenopausal women with fibromyalgia: comparison with healthy)Tj
T*
[(women. )54.9 (Ann Rheum Dis 2001;60:21-6.)]TJ
-0.00011 Tc -2.15 -1.25 Td
[(25.)-750.1 (Hakkinen K, )54.8 (Alen M, Kallinen M, et al. Muscle CSA, force )]TJ
0 Tc 2.15 -1.25 Td
(production, and activation of leg extensors during isometric and)Tj
T*
(dynamic actions in middle-aged and elderly men and women. )Tj
-0.02991 Tw T*
[(J Aging )-54.8 (Physical Activity )-54.9 (1998;6:232-47.)]TJ
0.02499 Tw -2.15 -1.25 Td
[(26.)-750 (Hakkinen K, Kallinen M, Izquierdo M, et al. Changes in )]TJ
-0.00011 Tc 2.15 -1.25 Td
[(agonist-antagonist EMG, muscle CSA)-220.2 (and force during strength)]TJ
0 Tc T*
[(training in middle-aged and older people. J )54.8 (Appl Physiol)]TJ
0 Tw T*
(1998;84:1341-9.)Tj
0.0249 Tw -2.15 -1.25 Td
[(27.)-750 (Hakkinen K, Pakarinen )54.8 (A, Kraemer )17.7 (WJ, Hakkinen )54.8 (A, )17.7 (V)111.1 (alkeinen H,)]TJ
2.15 -1.25 Td
[(Alen M. Selective muscle hypertrophy)64.9 (, changes in EMG and force)]TJ
T*
(and serum hormones during strength training in older women. )Tj
T*
[(J )54.9 (Appl Physiol 2001;91:569-80.)]TJ
-2.15 -1.25 Td
[(28.)-750 (Durnin J, )17.7 (W)79.8 (omersley )36.8 (Y)129.1 (. Body fat assessed from total body density)]TJ
2.15 -1.25 Td
(and its estimation from skinfold thickness: measurements on 481)Tj
T*
(men and women aged from 16 to 72 years. Br J Nutr 1967;)Tj
0 Tw T*
(32:77-97.)Tj
-0.00011 Tc 0.02499 Tw -2.15 -1.25 Td
[(29.)-750.1 (Nicklas BJ, R)39.7 (yan )54.8 (AJ, )17.7 (T)34.8 (reuth MM, et al. )17.7 (T)69.7 (estosterone, growth)]TJ
2.15 -1.25 Td
(hormone and IGF-I response to acute and chronic resistive exercise)Tj
0 Tc T*
(in men aged 55-70 years. Int J Sports Med 1995;16:445-50.)Tj
-2.15 -1.25 Td
[(30.)-750 (Kraemer )17.7 (WJ, H\344kkinen K, Newton R, et al. Ef)17.8 (fects of heavy )]TJ
2.15 -1.25 Td
(resistance training on hormonal response patterns in younger vs.)Tj
T*
[(older men. J )54.9 (Appl Physiol 1999;87:982-92.)]TJ
-0.00011 Tc -2.15 -1.25 Td
[(31.)-750.1 (Fahey )17.7 (T)73.9 (,)-0.1 ( Ralph R, Moungnee P)110.7 (, Mortara S. Serum testosterone,)]TJ
0 Tc 2.15 -1.25 Td
(body composition and strength of young adults. Med Sci Sports)Tj
T*
(Exerc 1976;8:31-4.)Tj
-0.00011 Tc -2.15 -1.25 Td
[(32.)-750.1 (W)79.7 (eiss L)73.9 (W)91.7 (, Cureton KJ, )17.7 (Thompson FN. Comparison of serum)]TJ
0 Tc 2.425 -1.25 Td
(testosterone and androstenedione responses to weight lifting in men)Tj
-0.275 -1.25 Td
[(and women. Eur J )54.9 (Appl Physiol 1983;50:413-9.)]TJ
-2.15 -1.25 Td
[(33.)-750 (Kraemer )17.8 (WJ, Gordon SE, Fleck SJ, et al. Endogenous anabolic)]TJ
-0.00011 Tc 2.15 -1.25 Td
(hormonal and growth factor responses to heavy resistance exercise)Tj
0 Tc T*
(in males and females. Int J Sports Med 1991;12:228-35.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(H\344kkinen, et al: T)54.9 (raining adaptation in FM)]TJ
0 Tw 60.9375 -0.0313 Td
(1295)Tj
ET
0 0 0 0 scn
/GS0 gs
103.04 59.08 407.5 -10.83 re
f*
0.5 w
103.04 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
97 0 obj
<>
endobj
121 0 obj
<>
endobj
80 0 obj
<>
endobj
76 0 obj
<>
endobj
78 0 obj
<>
endobj
91 0 obj
<>stream
HV pTE{3 09 G"&M8 Cppΐ"J5.,Ųȃe5)ŢZP֢Y
MVmttgwQcstJG+N}u4
beq| }h}*t#8Ŝ²&
Y4XʱƫOq5?9ڷ~KƼ<8U!E><"6OMC%X^{Aѫbm[5c[Z: |EVJ9R ,*VdѺ0;?n,uԡ21Uچ(eEgHl2A21K\qڥÇuH`녉X]831(AYkBcU0rxП0<9ʉ- _Z͢r4w%bE{K@<\i<=oͥWkt1~J'8+Jg{Ebb>wXP{b:ZzuЁ>1q'c:V3n3g9.㊈}@Q !qZL٭]22L= SΫjdQtybL29[7UE]^EHvJ QȺ0ػD
p DH|_2^&JC,e2[=^|Ց,Udͱ>a繗]B%̽^c rlV'l'>Οs8s:nCn.!Q GHHVm Z FJXT%
OV2_dH.ʓF^7OJYj:AݡkS*ZvWȔHeLZdmAK$`GQ6P2^ѹ-ky*Vlb~;اy09\af?>"" Tֹ-sʌ8Q(b"2sk9X-bNKmqdl%uB A]^n[埥)ȣw24WtOTeE٪lWPC]RwYVZj%,-js}GO4c;;9ky~ً
P>\uV`">D:ȵO0H['aH#%+xa]"E"ۺ^ҞgZgj0o1\UcHS<%k9{2lFzG7nCv)mڴ~e|bcMU@͌fCzlR `
yQ3iK/-~am>.yuNLzUQ
Z͈2-ȸ}ɡ<g}<ƫ_flԷJ_lbppQ(m3S<ȋt_,s<٦\lL3a2[f5G#c0C3Bߕ/΅i$8o*"{VYfg&v9 h[٤JS 4+6$7lΘriKX(5|$0S7cAF(<3MYޝ⭷|QK1֫}ZɮO^͒{zs_wK5yؘU6Efa:
k+E8f a;8vk=#FӒ`đnCeffO)DhJQv,
X`Q[idF^Ǵv*2e{I(5Տ4O?̘-]}>HҨ:I"[";bRMcz^1o(DkQ-X/>BZhA2ۺeۓII$IJ#''@ʡO
1
8O)?ᜄKsƤGH;d5p}_嫥jeՠnQWƶɎuuf?Nc
)H[J2s@ژ=HUk+{GEJ_\2Sea$7#6x}tTI*ݬs~_Ԧy9?)ӯh95{~WT:t7ڐ1LWsCqLmz7u\Օ$zYy%[M a[2`D56i
)OG 5q+anI3)nJ[Pux%P3`7QIIfÌ0m]Bg4|{={v{w 2Z_;gQE f<P8G`;;k#2R
Fu9[eX,wsO@։.rk#ւc[q3ba1Aoug/ _=s0
hn=?9'!˿'%:tG ':q BLPǰP(;eȫ߰eQX/ X|b{3&wz$H8,v&#,X